Interobserver reproducibility of immunohistochemical HER-2/neu evaluation in human breast cancer: The real-world experience

International Journal of Biological Markers

Volumn 19, Issue 2, 2004, Pages 147-154

  Paradiso, A ^a   Marubini, E ^b   Verderio, Paolo ^c   Cortese, M E ^c   De Paola, F ^d   Silvestrini, R ^c   Simone, G ^a   Marzullo, F ^a   Menard, S ^c   Tagliabue, E ^c   Tomasich, G ^c   Mottolese, M ^e   Querzoli, P ^f   Bevilacqua, G ^g   Campani, D ^g   Granato, A ^d   Marinaro, E ^h   Folicaldi, S ⁱ   Naldi, N ^j   Ludovini, V ^k   Maioli, P ^l   Bernardi, L ^m   more..

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d MORGAGNI PIERANTONI HOSPITAL   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF FERRARA   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h GALLIERA HOSPITAL   (Italy)

ⁱ AUSL Imola   (Italy)

^j Azienda Ospedaliera   (Italy)

^k POLICLINICO MONTELUCE   (Italy)

^l Ospedale Civile   (Italy)

^m OSPEDALE DEGLI INFERMI   (Italy)

more..

Author keywords

Breast cancer; Immunohistochemical HER 2 neu; Intra interobserver reproducibility; Quality control

Indexed keywords

ARTICLE; BREAST CANCER; CALCULATION; CLASSIFICATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; ITALY; LABORATORY; OBSERVER VARIATION; ONCOGENE NEU; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REFERENCE VALUE; REPRODUCIBILITY; STATISTICAL ANALYSIS;

EID: 4243180460     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080401900210     Document Type: Article

References (19)

1. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37: S3-S8.
2. Slamon D, Pegram M. Rationale for trasuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001; 28: 38-44.
3. Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use?. J Pathol 2003; 199: 411-7.
4. Schnitt SJ, Jacobs TW. Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol 2001; 116: 806-10.
5. Wisecarver JL. HER-2 neu testing comes of age. Am J Clin Pathol 1999; 111: 299-301.
6. Rhodes A, Jasani B, Couturier J, et al. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2 neu expression in breast cancer. Am J Clin Pathol 2002; 117: 81-9.
7. Gancberg D, Lespagnard L, Rouas G, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas: correlation with oncogene amplification in 160 cases. Am J Clin Pathol 2000; 116: 675-82.
8. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002; 94: 855-7.
9. Hanna W, Kahn HJ, Trudeau M. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. Mod Pathol 1999; 12: 827-34.
10. Hsu CY, Ho DM, Yang CF, Lai CR, Yu IT, Chiang H. Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO Hercep Test. Am J Clin Pathol 2002; 118: 693-8.
11. Hoang MP, Sahin AA, Ordonez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000; 113: 852-9.
12. Gancberg D, Jarvinen T, di Leo A, et al. Evaluation of HER-2/NEU protein expression in breast cancer immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat 2002; 74: 113-20.
13. Paradiso A, Volpe S, Iacobacci A, et al. Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT). Int J Biol Markers 2002; 17: 200-13.
14. Fleiss JL. Statistical methods for rates and proportions (2nd ed.). New York: Wiley and Sons, 1981.
15. Holman CDJ: Analysis of interobserver variation on a programmable calculator. Am J Epidemiol 1984; 120: 154-61.
16. Landis R, Koch G. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 117-27.
17. Santinelli A, Baccarini M, Colanzi P, Stramazzotti D, Fabris G. Immunohistochemical evaluation of HER-2/neu expression in infiltrating breast carcinoma: a study of reproducibility. Anal Quant Cytol Histol 2002; 24: 54-62.
18. Konecny G, Slamon DJ. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Huntingt) 2002; 16: 1576, 1578.
19. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel experience. J Natl Cancer Inst 2002; 94: 852-4.